Skip to main content
Skip to main navigation menu
Skip to site footer
Open Menu
Home
Editorial Policies
About the Journal
Journal History
Editorial Process
Publishing Agreement, Copyright Notice and Copyright Clearance Fees
Publication Ethics and Publication Malpractice Policies
Data Sharing and Availablity
Use of Artificial Intelligence (AI)
Article Withdrawal, Retractions and Corrections
Appeals, Complaints, and Disputes
Privacy Statement
Author Guidelines
Instructions to Authors
Submission Preparation Checklist
Article Types
JAFES Downloadable Forms
Issues
Current
Early Access Articles
Forthcoming Articles [In Press]
Archives
Editors
Editorial Team
Editors' Roles
Editorial Conflict of Interest Disclosure
Announcements
Advertisement Policy
Peer Review
Search
Search
Register
Login
Search
Search
Home
/
Search
Search
Search articles for
Advanced filters
Published After
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
January
February
March
April
May
June
July
August
September
October
November
December
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Published Before
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
January
February
March
April
May
June
July
August
September
October
November
December
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
By Author
Search
1 - 5 of 5 items
LIRAGLUTIDE 3.0 mg AS AN ADJUNCT TO INTENSIVE BEHAVIOR THERAPY IN INDIVIDUALS WITH OBESITY
SCALE IBT 56-WEEK RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL
Thomas Wadden, Jena Shaw Tronieri, Danny Sugimoto, Michael Taulo Lund, Pernille Auerbach, Camilla Jensen, Domenica Rubino, Cyrus Q. Pasamba
9-10
2022-05-04
EFFECT OF WEIGHT LOSS ON PHYSICAL FUNCTION MEASURED BY THE 6-MINUTE WALKING DISTANCE TEST IN INDIVIDUALS WITH OBESITY
RESULTS FROM THE SCALE IBT TRIAL OF LIRAGLUTIDE 3.0 mg
Cyrus Pasamba, Mercerose Puno
46
2022-06-08
OUTCOMES IN EARLY RESPONDERS ACHIEVING ≥5% WEIGHT LOSS AT 16 WEEKS WITH LIRAGLUTIDE 3.0 mg AS AN ADJUNCT TO INTENSIVE BEHAVIOUR THERAPY (IBT) IN INDIVIDUALS WITH OBESITY IN THE SCALE IBT TRIAL
Thomas Wadden, Pernille Auerbach, Lars Endahl, Jena Shaw Tronieri, Dorthe Skovgaard, Danny Sugimoto, Domenica Rubino, Ahsan Shoeb
48
2022-06-08
WEIGHT LOSS WITH LIRAGLUTIDE 3.0 mg VERSUS PLACEBO FOR INDIVIDUALS WHO ADHERE TO THE TRIAL DRUG
A SECONDARY ANALYSIS FROM SCALE IBT
Jena Shaw Tronieri, Thomas Wadden, Danny Sugimoto, Michael T. Lund, Pernille Auerbach, Lars Endahl, Domenica Rubino, Cyrus Pasamba
46-47
2022-06-08
EFFICACY AND SAFETY OF LIRAGLUTIDE 3.0 mg IN INDIVIDUALS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (T2D) TREATED WITH BASAL INSULIN
THE SCALE INSULIN TRIAL
W. Timothy Garvey, Andreas Birkenfeld, Dror Dicker, Geltrude Mingrone, Susie Pedersen, Altynai Satylganova, Dorthe Skovagaard, Danny Sugimoto, Niels Zeuthen, Ofri Mosenzon, Ahsan Shoeb
12
2022-05-04
1 - 5 of 5 items
AFES COUNTRY MEMBERS
JAFES IS INDEXED IN
SCIMAGO JOURNAL AND COUNTRY RANK
ADVERTISEMENT
OUR COMMITMENT TO AUTHORS AND READERS
Information
For Readers
For Authors
For Librarians
Make a Submission
Make a Submission
Keywords